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rn an era of rapidly increasing societal costs for medical care,
ur profession is asked more and more to provide evidence
or the value of care. Cardiovascular disease is the leading
ause of mortality in the Western world, and its incidence is
ncreasing rapidly in developing countries. Cardiology is the
ost prominent specialty that treats acutely ill patients, and
ur care involves costly cognitive and technical components.
ccordingly, cardiovascular medicine is a particularly attrac-
ive target for intense scrutiny of the value of care.
HOOSING THE YARDSTICKS
etrics involved in constructing a value yardstick vary
epending on the stakeholder. Institutions, physicians, so-
iety, patients and their families all represent important
takeholders in this discussion. For institutions and physi-
ians, the metrics available for assessing the value of care
ave been studied more rigorously for cardiovascular disease
han for any other disease. Widely accepted guidelines for
cute myocardial infarction have been published and are
ontinually updated by the College. These guidelines in-
lude pre-hospital care and triage, in-hospital treatment,
ursing, reperfusion strategies, risk stratification, post-
ospital care, and secondary prevention. Adherence to the
uidelines can be measured and outcomes assessed, includ-
ng morbidity, mortality, and costs. The metrics used to
easure quality in acute coronary care include early and
ong-term morbidity/mortality, resource utilization, length
f stay, return to work or full activity, and patient and family
atisfaction. These outcome measures are increasingly avail-
ble to third-party payers and the public.
ATA REVEAL VALUE
s we think about the impact of our cardiovascular perfor-
ance on outcomes for patients, their families, and society
like, what are the observations that could be made?
Regardless of the metrics used, patients, families and
ociety have benefited enormously. Cardiovascular mortality
as dropped significantly in the past 10 to 20 years. In data
vailable from 1979 to 2003, the death rate in men fell from
90 deaths per thousand to 440 deaths per thousand dAmerican Heart Association statistics) (1). This drop
ccurred despite the fact that the population grew older
ith an increasing incidence of obesity and diabetes.
Modern cardiovascular care has been responsible for a
arge decrease in hospital mortality from acute ischemic
vents. Randomized trials in the 1980s typically docu-
ented in-hospital mortality rates of 8% to 10% compared
ith more recent trials in which mortality rates of 5% are
requently observed. Even in the highest-risk patients, those
ith cardiogenic shock, mortality has decreased over the
ast two decades from between 80% and 90% to approxi-
ately 50%. Again, it must be kept in mind that these
mprovements have occurred despite treating older and
icker patients.
ODERN CARE IMPROVES OUTCOMES
particularly dramatic change has been the improved
utcomes and decreased risk of intracerebral hemorrhage in
atients treated with primary percutaneous intervention.
his change has fostered the development of regional
etworks and centers that emphasize expert cardiovascular
are and have a major objective of improving outcome by
ptimizing the process of care. A good example is the
ositive impact of decreasing door-to-balloon time. With
cute myocardial infarctions (MIs), the use of drug-eluting
tents has dramatically reduced the need for subsequent
rocedures to treat restenosis.
Prior to modern cardiac care, patients were put on bed
est for several weeks after MI, which exposed them to
ultiple risks—some medical, such as a pulmonary embo-
ism or hospital-acquired pneumonia. Other risks were
nancial, such as loss of a job. Today, after an acute MI, the
ajority of patients can be discharged within three to four
ays. The pace of re-entry into full life often occurs within
few weeks.
Other equally dramatic advances have occurred. In pa-
ients with large MIs accompanied by congestive heart
ailure, selected patients have marked improvement in
unctional outcome when they are treated with cardiac
esynchronization therapy. In some patients with myocar-
ial infarction and decreased left ventricular ejection frac-
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President’s Page October 3, 2006:1469–70ion, implantation of a defibrillator can significantly improve
urvival by treating lethal ventricular arrhythmias.
These seminal advances in the treatment of acute cardio-
ascular disease have been hard won and have required time,
nergy, and evidence-based randomized clinical trials. Of
qual importance, they required the full participation of
ociety and patients as new approaches were tested and
alidated.
Whether we measure in-hospital morbidity and mortal-
ty, improved methods for the restoration of arterial patency,
hortened length of stay, or prevention of sudden cardiac
eath or congestive heart failure, we have successfully
elivered modern cardiovascular care to millions of patients.
he future looks even brighter with new approaches for
ptimizing myocyte recovery/repair, development of net-
orks to guarantee rapid access to all patients with acute
yocardial infarction, and prevention of the initial trigger ofhe event.In terms of impact on society, acute coronary care
epresents the ultimate expression of value in medical care,
n observation that must not be forgotten in the current
ush to constrain costs and increase value. We must remind
egislators, government officials, and payers of the true costs
f not having an experienced dedicated cardiology care team
vailable when they or their loved ones have their own MI.
ddress correspondence to: Dr. Steven E. Nissen, American
ollege of Cardiology, c/o Cathy Lora, 2400 N Street, NW,
ashington, DC 20037.
EFERENCE
. American Heart Association. American Heart Association Statistical
Fact Sheets. Available at: http://www.americanheart.org. Accessed
August 20, 2006.
